Diclofenac sodium-loaded solid lipid nanoparticles prepared by emulsion/solvent evaporation method

2010 ◽  
Vol 13 (6) ◽  
pp. 2375-2386 ◽  
Author(s):  
Dongfei Liu ◽  
Sunmin Jiang ◽  
Hong Shen ◽  
Shan Qin ◽  
Juanjuan Liu ◽  
...  
2016 ◽  
Vol 2016 ◽  
pp. 1-5 ◽  
Author(s):  
Mojtaba Abrishami ◽  
Majid Abrishami ◽  
Asma Mahmoudi ◽  
Navid Mosallaei ◽  
Mohammad Vakili Ahrari Roodi ◽  
...  

Purpose. In order to improve the drug availability after intravitreal administration, solid lipid nanoparticles (SLNs) containing diclofenac were prepared. Methods. In this experimental study, 18 albino rabbits were included. In right and left eyes of all rabbits, SLNs containing diclofenac and commercial form of diclofenac (0.3 mg drug) were intravitreally injected, respectively. One, four, twelve, twenty-four, and forty-eight hours after injection, vitreous and aqueous humor samples were obtained in all cases. Then, the concentration of diclofenac sodium was evaluated in all samples. Results. Size of nanoparticles was around 170 nm after preparation. Drug concentration in eyes injected with SLNs was significantly higher than left eyes injected with commercial formulation up to 4 hours after intravitreal injection (p<0.05). Diclofenac was quantified in samples up to 48 hours after intraocular injection. Four hours after intravitreal injection, the concentration of diclofenac in vitreous and aqueous humor of eyes receiving SLNs was, respectively, 2.5 and 6.5 times higher than eyes injected with commercial form of drug. Conclusions. Here, we demonstrate the potential of SLNs as a carrier of diclofenac for intraocular injection in order to prevent the systemic effects of the drug, increase the injection intervals, and improve the patient compliance.


Author(s):  
Rohan R. Vakhariya ◽  
Vijay R. Salunkhe ◽  
Dheeraj S. Randive ◽  
Mangesh A. Bhutkar ◽  
Somnath D. Bhinge

Background: Ramipril, an antihypertensive drug exhibit 28% of oral bioavailability and also expelled quickly through the kidneys. Moreover, numerous side effects reported by the ramipril such as, hypotension (postural), increasing potassium level, and angioedema, when presented as an immediate dosage form. Hence, to conquer the side-effects associated with the drug and to increase its bioavailability. Objective: The intention of the proposed approach was to design, develop and optimize Ramipril loaded solid lipid nanoparticles. Methods: Solvent emulsification and evaporation method were employed to prepare Ramipril loaded solid lipid nanoparticles containign stearic acid and phosphatidylcholine as a lipid and surfactant respectively. The prepared formulations have been confirmed with particle size analyzer, %entrapment efficiency, Zeta Potential, SEM, X-ray diffraction study, FTIR, NMR spectroscopy, in-vitro release study and stability study. Result: The obtained results were noted to be within the standard limits. No interaction between Ramipril and other excipients, were confirmed with the FT-IR study of the formulations. Particle size analyzer confirmed that the nanometer size of prepared formulations ranges between 200-350nm. Percent entrapment efficiency was observed in the range of 70.61–91.60%. Entrapment and particle size results of the nanoparticles from R5 batch was an adjudged. The designed formulation noted 70.50% cumulative drug release within a period of 7hrs. The designed batch showed mean of zeta potential at-29.4 mV exhibiting good stability of formulation. Conclusion: The developed formulation was found to be stable and safe, and represents a promising system for the sustained and controlled delivery of Ramipril.


Sign in / Sign up

Export Citation Format

Share Document